Solbec Pharmaceuticals Ltd's Anthony Kiernan has announced his retirement as chairman and director of the company.
Mr Kiernan has been director of the Osborne Park-based company since March 2003 and is stepping down to pursue other business opportunities.
Solbec has commenced the process of identification and selection of a new replacement chairman, but in the meantime, Russell Barnett will act as interim chairman.
Mr Barnett has over 15 years experience in technology commercialisation, innovation management, new venture creation and venture capital markets with a wide range of organisations throughout the Asia Pacific region.
Mr Barnett holds a number of other directorships including chairman of Kirke Securities Ltd and non-executive
director of Rewire Therapies Ltd.
With the assistance of a $2.26 million Australian Government Commercial Ready grant, Solbec is currently progressing its key project, Coramsine, for the treatment of advanced solid tumours.
In addition to human health, Coramsine has potential application to animal health and diagnostics.
